INTERNATIONAL JOURNAL OF CURRENT RESEARCH IN CHEMISTRY AND PHARMACEUTICAL SCIENCES
(p-ISSN: 2348-5213: e-ISSN: 2348-5221)
www.ijcrcps.com
(A Peer Reviewed, Referred, Indexed and Open Access Journal)
DOI: 10.22192/ijcrcps Coden: IJCROO(USA) Volume 11, Issue 2- 2024

Review Article

DOI: http://dx.doi.org/10.22192/ijcrcps.2024.11.02.003

Improving Outcomes: Integrated Strategies for Diabetes and Sickle Cell Anemia

[*]Emmanuel Ifeanyi Obeagu[1] and Getrude Uzoma Obeagu[2]
[1]Department of Medical Laboratory Science, Kampala International University, Uganda.
[2]School of Nursing Science, Kampala International University, Uganda.
[*]Corresponding author: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda,
emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

Abstract

The coexistence of diabetes and sickle cell anemia poses a unique and complex healthcare challenge, necessitating integrated strategies for improved outcomes. This review explores the bidirectional impact of these conditions on each other's progression, emphasizing the need for a comprehensive, multidisciplinary approach. Investigating pathophysiological interactions, lifestyle interventions, pharmacological approaches, and coordinated management, the article delves into current research findings and promising models of care. The integration of nutritional strategies, physical activity programs, and novel therapies is examined alongside the role of multidisciplinary care teams and patient empowerment. Challenges in implementation, research gaps, and future directions are also discussed, highlighting the potential for personalized medicine to optimize outcomes for individuals living with both diabetes and sickle cell anemia. This review serves as a comprehensive exploration of integrated care strategies, aiming to guide healthcare providers, researchers, and policymakers toward more effective and holistic management approaches for this complex patient population.

Keywords: Integrated Care, Diabetes, Sickle Cell Anemia, Multidisciplinary Approach, Coordinated Management

Introduction

The coexistence of diabetes mellitus and sickle cell anemia represents a clinical intersection that demands a nuanced and integrated approach to healthcare. Both conditions, characterized by chronicity and systemic impact, converge to create a complex medical landscape for affected individuals. Diabetes, a metabolic disorder, and sickle cell anemia, a genetic hematological disorder, often manifest concurrently, amplifying the challenges associated with their management. Diabetes, with its rising global prevalence, and sickle cell anemia, predominantly affecting

populations of African descent, collectively contribute to a substantial burden on healthcare systems. The intersection of these conditions is not merely coincidental; rather, it introduces synergistic challenges that necessitate specialized attention. Understanding the intricate interplay between diabetes-induced hyperglycemia and sickle cell-induced hemoglobin abnormalities is critical. These pathophysiological interactions extend beyond conventional considerations, influencing vascular function, inflammatory responses, and oxidative stress.[1-26]

The bidirectional impact of diabetes and sickle cell anemia on each other's progression underscores the rationale for integrated care. Shared risk factors, exacerbated complications, and the potential for simultaneous therapeutic interventions highlight the need for a cohesive and coordinated management approach. This review aims to synthesize current research findings and highlight successful integrated care models, offering insights into the evolving landscape of diabetes and sickle cell anemia management.

Pathophysiological Interactions

The coexistence of diabetes and sickle cell anemia introduces intricate pathophysiological interactions that extend beyond the conventional understanding of these individual conditions. The synergy between the metabolic dysregulation in diabetes and the genetic hemoglobin abnormality in sickle cell anemia creates a complex interplay, impacting vascular function, inflammatory responses, and oxidative stress.Diabetes is notorious for inducing microvascular and macrovascular complications, affecting small and large blood vessels. Concurrently, sickle cell anemia exacerbates vascular dysfunction through the formation of rigid, sickle-shaped red blood cells, leading to vaso-occlusive events.[27-48]

The prothrombotic state associated with diabetes is compounded by the presence of sickle cell anemia, further elevating the risk of thromboembolic events. Sickle cell-induced hemolysis and microvascular occlusion contribute to impaired oxygen delivery, aggravating the tissue hypoxia already observed in diabetes-related complications. Diabetes is characterized by a state of chronic low-grade inflammation, contributing to insulin resistance and end-organ damage. Sickle cell anemia, through recurrent vaso-occlusive crises, triggers episodic inflammatory responses. Interactions between the adaptive and maladaptive arms of the immune system in both conditions create a milieu of heightened inflammation, potentially accelerating the progression of each other.Both diabetes and sickle cell anemia contribute to mitochondrial dysfunction, leading to increased production of reactive oxygen species (ROS). The antioxidant capacity is compromised in sickle cell anemia due to chronic hemolysis, while diabetes exacerbates oxidative stress through hyperglycemia-induced ROS production. Diabetes and sickle cell anemia independently contribute to impaired nitric oxide bioavailability, crucial for maintaining vascular tone. The combined effect further aggravates endothelial dysfunction. Increased expression of adhesion molecules in both conditions promotes leukocyte adhesion, contributing to a proinflammatory and prothrombotic endothelial phenotype.[49-59]

Inflammation and Oxidative Stress

Diabetes is characterized by persistent low-grade inflammation, marked by elevated levels of proinflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α).[60] Chronic hyperglycemia triggers the activation of inflammatory pathways, contributing to insulin resistance and organ damage. In sickle cell anemia, recurrent vaso-occlusive events induce episodic inflammatory responses. Ischemia-reperfusion injury during sickling and unscheduled hemolysis contribute to the release of inflammatory mediators. The coexistence of diabetes and sickle cell anemia creates a milieu where chronic inflammation from diabetes synergizes with episodic inflammatory responses in sickle cell anemia, potentially accelerating vascular complications. Hyperglycemia contributes to immune dysregulation, with altered function of immune cells such as macrophages

and T cells. Persistent immune activation contributes to chronic inflammation and tissue damage.

The repetitive nature of vaso-occlusive crises in sickle cell anemia leads to adaptive immune responses, with increased leukocyte activation and adhesion to the vascular endothelium.[61] Chronic hemolysis exposes the immune system to increased levels of cell-free hemoglobin, further activating inflammatory pathways. The coexistence of diabetes and sickle cell anemia may lead to a state of both adaptive and maladaptive immune activation, potentially heightening the risk of immune-mediated complications. Diabetes and sickle cell anemia independently contribute to mitochondrial dysfunction, leading to increased production of reactive oxygen species (ROS). Hyperglycemia in diabetes enhances electron leakage from the mitochondrial electron transport chain, promoting ROS generation. Sickle cell anemia, characterized by chronic hemolysis, reduces the antioxidant capacity of plasma, making individuals more susceptible to oxidative stress. Diabetes further exacerbates oxidative stress by reducing the activity of antioxidant enzymes such as superoxide dismutase and catalase. The confluence of oxidative stress from both conditions creates a cumulative burden, contributing to endothelial dysfunction and amplifying the risk of complications such as cardiovascular disease.

Lifestyle Interventions

Encourage a balanced diet that meets the nutritional needs of individuals with diabetes and sickle cell anemia.[62] Emphasize the importance of a diet rich in fruits, vegetables, whole grains, and lean proteins. Stress the significance of adequate hydration to prevent dehydration, particularly during sickling episodes. Monitor fluid intake to avoid complications related to increased blood viscosity. Consider targeted nutritional supplementation to address specific deficiencies common in both conditions, such as vitamin D, folic acid, and omega-3 fatty acids. Collaborate with nutritionists to tailor supplementation based on individual needs and potential medication interactions. Develop individualized exercise plans that accommodate the unique needs and limitations of individuals with both diabetes and sickle cell anemia. Incorporate a mix of aerobic exercises, strength training, and flexibility exercises.

Implement continuous monitoring during physical activity to detect early signs of dehydration, hypoxia, or other complications.[63] Adjust exercise intensity and duration based on individual responses and health status. Provide comprehensive education on the benefits of regular physical activity in improving insulin sensitivity, cardiovascular health, and overall well-being. Empower individuals to recognize and manage potential exercise-related complications. Stress the importance of regular blood glucose monitoring, especially during sickling crises or other health stressors. Empower individuals to recognize patterns and make informed decisions regarding insulin or oral hypoglycemic medication adjustments. Establish individualized glycemic targets in collaboration with healthcare providers, considering the dynamic nature of sickle cell anemia and its impact on glucose metabolism. Adjust treatment plans based on variations in health status and treatment response.

Recognize the psychosocial impact of living with dual conditions and integrate mental health support into care plans. Utilize behavioral strategies, such as cognitive-behavioral therapy, to address stressors, depression, and anxiety. Implement adherence counseling to enhance medication compliance, lifestyle modifications, and regular healthcare follow-ups. Foster open communication between healthcare providers and individuals to address barriers to adherence. Provide comprehensive disease education to enhance individuals' understanding of both diabetes and sickle cell anemia. Address misconceptions and promote informed decision-making regarding lifestyle choices. Encourage self-monitoring practices, including tracking symptoms, monitoring blood glucose levels, and recognizing early signs of complications.

Facilitate the development of personalized action plans for managing day-to-day challenges.

Physical Activity Programs

Physical activity is a cornerstone of health for individuals with diabetes and sickle cell anemia. Tailored exercise programs can improve cardiovascular health, insulin sensitivity, and overall well-being. However, due to the unique challenges posed by these coexisting conditions, careful consideration and individualization of physical activity plans are crucial. Initiate physical activity programs following thorough consultation with healthcare providers, including hematologists, endocrinologists, and exercise physiologists. Consider the individual's current health status, hemoglobin levels, cardiovascular fitness, and any history of exercise-related complications. Design exercise prescriptions that accommodate the specific needs and limitations of individuals with both diabetes and sickle cell anemia. Include a mix of aerobic exercises (e.g., walking, swimming), strength training, and flexibility exercises. Emphasize gradual progression to avoid sudden increases in intensity that could trigger sickling events or compromise glycemic control. Monitor closely for signs of fatigue, dehydration, or pain during and after exercise.[62]

Implement continuous monitoring during physical activity to detect early signs of dehydration, hypoxia, or other complications. Utilize wearable devices and self-monitoring tools to track heart rate, oxygen saturation, and blood glucose levels. Conduct regular assessments of cardiovascular fitness, muscular strength, and flexibility to adapt exercise programs accordingly. Adjust exercise intensity, duration, and type based on individual responses and any changes in health status. Integrate rest periods within exercise sessions to prevent excessive fatigue and reduce the risk of sickling events. Encourage individuals to listen to their bodies and modify activity levels as needed. Emphasize the importance of proper hydration before, during, and after exercise to mitigate the risk of dehydration, a common trigger for sickling events. Provide guidelines on fluid intake based on individual needs and environmental conditions. Educate individuals on the dynamic interplay between exercise and blood glucose levels. Encourage self-monitoring and adjustment of insulin or oral hypoglycemic medications as needed before and after exercise. Educate individuals on recognizing early signs of complications, such as pain crises or hypoglycemia, during physical activity. Develop action plans for managing symptoms and seeking prompt medical attention when necessary. Consider individualized exercise programs tailored to the preferences, fitness levels, and specific health concerns of each person. Take into account factors such as age, comorbidities, and individual goals. Explore the potential benefits of group exercise sessions, fostering a supportive and motivating environment. Ensure that group activities are adaptable to individual needs and that supervision is provided to monitor for complications.[63]

Pharmacological Approaches

Managing diabetes and sickle cell anemia concurrently often requires a thoughtful integration of pharmacological therapies.[65] Due to the distinct pathophysiological mechanisms of each condition, medications must be selected with consideration for their individual and synergistic effects. Tailor antidiabetic medications to the unique needs and response patterns of individuals with diabetes and sickle cell anemia. Considerations should include the type of diabetes, hemoglobin levels, and potential interactions with medications used to manage sickle cell anemia. Individualize insulin therapy based on glycemic control targets, lifestyle factors, and the presence of complications. Consider continuous glucose monitoring to optimize insulin dosing and prevent hypoglycemia during sickling events. Select oral hypoglycemic agents judiciously, considering their safety profile and potential interactions with medications used in sickle cell anemia. Monitor for any adverse effects and adjust medication regimens accordingly.

Prescribe analgesics for pain management during sickle cell crises, ensuring compatibility with antidiabetic medications.[65]Non-steroidal anti-inflammatory drugs (NSAIDs) should be used cautiously due to their potential impact on renal function and increased risk of gastrointestinal bleeding. Consider opioid therapy for moderate to severe pain during sickle cell crises, balancing the need for effective pain relief with the risk of dependence and respiratory depression. Monitor closely for opioid-related side effects and adjust doses based on individual responses.Evaluate the potential use of hydroxyurea, a disease-modifying agent in sickle cell anemia, considering its impact on hematological parameters and potential benefits for reducing pain crises. Monitor for potential interactions with antidiabetic medications and adjust doses accordingly. Explore emerging pharmacological therapies aimed at inducing fetal hemoglobin, which has been associated with milder clinical courses in sickle cell anemia.Balance the potential benefits of these agents with their safety and potential interactions with diabetes medications.

Address comorbid hypertension commonly observed in individuals with diabetes and sickle cell anemia.[66]Choose antihypertensive medications with favorable profiles regarding their impact on renal function and potential interactions with other medications. Manage dyslipidemia associated with diabetes through the use of statins and other lipid-lowering agents. Monitor for potential adverse effects, especially in the context of sickle cell anemia-related complications. Facilitate interdisciplinary collaboration between hematologists, endocrinologists, and other specialists to ensure coordinated medication management. Communicate regularly to adjust medication regimens based on changes in health status and treatment response. Implement individualized monitoring plans for medication effectiveness and safety, taking into account the dynamic nature of both diabetes and sickle cell anemia. Periodic medication reviews should be conducted to assess the need for adjustments based on individual responses and emerging clinical data.

Conclusion

The complex interplay between diabetes and sickle cell anemia necessitates a comprehensive and integrated approach to healthcare, encompassing lifestyle interventions, pharmacological strategies, and coordinated management. The synergy of these conditions demands a personalized and multidisciplinary approach that addresses their unique pathophysiological interactions and minimizes the risk of complications. Nutritional strategies, physical activity programs, and behavioral interventions play a pivotal role in optimizing outcomes. Tailored exercise plans, in particular, promote cardiovascular health and insulin sensitivity while minimizing the risk of sickling events.

References

1. Obeagu EI, Ochei KC, Nwachukwu BN, Nchuma BO. Sickle cell anaemia: a review. Scholars Journal of Applied Medical Sciences. 2015;3(6B):2244-2252.
2. Obeagu EI. Erythropoeitin in Sickle Cell Anaemia: A Review. International Journal of Research Studies in Medical and Health Sciences. 2020;5(2):22-8.
3. Obeagu EI. Sickle Cell Anaemia: Haemolysis and Anemia. Int. J. Curr. Res. Chem. Pharm. Sci. 2018;5(10):20-1.
4. Obeagu EI, Muhimbura E, Kagenderezo BP, Uwakwe OS, Nakyeyune S, Obeagu GU. An Update on Interferon Gamma and C Reactive Proteins in Sickle Cell Anaemia Crisis. J Biomed Sci. 2022;11(10):84.
5. Obeagu EI, Bunu UO, Obeagu GU, Habimana JB. Antioxidants in the management of sickle cell anaemia: an area to be exploited for the wellbeing of the patients. International Research in Medical and Health Sciences. 2023 Sep 11;6(4):12-7.
6. Obeagu EI, Ogunnaya FU, Obeagu GU, Ndidi AC. Sickle cell anaemia: a gestational enigma. Migration. 2023;17:18.
7. Obeagu EI. An update on micro RNA in sickle cell disease. Int J Adv Res Biol Sci. 2018;5:157-8.

8. Obeagu EI, Babar Q. Covid-19 and Sickle Cell Anemia: Susceptibility and Severity. J. Clinical and Laboratory Research. 2021;3(5):2768-0487.
9. Obeagu EI, Getrude U. Obeagu.,(2023). Evaluation of Hematological Parameters of Sickle Cell Anemia Patients with Osteomyelitis in A Tertiary Hospital in Enugu, Nigeria. Journal of Clinical and Laboratory Research.;6(1):2768-0487.
10. Obeagu EI, Dahir FS, Francisca U, Vandu C, Obeagu GU. Hyperthyroidism in sickle cell anaemia. Int. J. Adv. Res. Biol. Sci. 2023;10(3):81-9.
11. Obeagu EI, Obeagu GU, Akinleye CA, Igwe MC. Nosocomial infections in sickle cell anemia patients: Prevention through multi-disciplinary approach: A review. Medicine. 2023 Dec 1;102(48):e36462.
12. Njar VE, Ogunnaya FU, Obeagu EI. Knowledge And Prevalence Of The Sickle Cell Trait Among Undergraduate Students Of The University Of Calabar. Prevalence.;5(100):0-5.
13. Swem CA, Ukaejiofo EO, Obeagu EI, Eluke B. Expression of micro RNA 144 in sickle cell disease. Int. J. Curr. Res. Med. Sci. 2018;4(3):26-32.
14. Obeagu EI. Depression in Sickle Cell Anemia: An Overlooked Battle. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(10):41-4.
15. Obeagu EI, Nimo OM, Bunu UO, Ugwu OP, Alum EU. Anaemia in children under five years: African perspectives. Int. J. Curr. Res. Biol. Med. 2023;1:1-7.
16. Obeagu EI. Sickle cell anaemia: Historical perspective, Pathophysiology and Clinical manifestations. Int. J. Curr. Res. Chem. Pharm. Sci. 2018;5(11):13-5.
17. Ifediora AC, Obeagu EI, Akahara IC, Eguzouwa UP. Prevalence of urinary tract infection in diabetic patients attending Umuahia health care facilities. J Bio Innov. 2016;5(1):68-82. links/5ae45fdfaca272ba507eb3c3/PREVALENCE-OF-URINARY-TRACT-INFECTION-IN-DIABETIC-PATIENTS-ATTENDING-UMUAHIA-HEALTH-CARE-FACILITIES.pdf.
18. Ugwu OP, Alum EU, Okon MB, Aja PM, Obeagu EI, Onyeneke EC. Ethanol root extract and fractions of Sphenocentrumjollyanum abrogate hyperglycaemia and low body weight in streptozotocin-induced diabetic Wistar albino rats. RPS Pharmacy and Pharmacology Reports. 2023;2(2):rqad010.
19. Obeagu EI, Obeagu GU. Utilization of Antioxidants in the management of diabetes mellitus patients. J Diabetes Clin Prac. 2018;1(102):2.links/5b6c2dec92851ca65053b74e/Utilization-of-Antioxidants-in-the-Management-of-Diabetes-Mellitus.pdf.
20. Obeagu EI, Okoroiwu IL, Obeagu GU. Some haematological variables in insulin dependent diabetes mellitus patients in Imo state Nigeria. Int. J. Curr. Res. Chem. Pharm. Sci. 2016;3(4):110-7.links/5ae4abee458515760ac07a13/Some-haematological-variables-in-insulin-dependent-diabetes-mellitus-patients-in-Imo-state-Nigeria.pdf.
21. Nwakuilite A, Nwanjo HU, Nwosu DC, Obeagu EI. Evaluation of some trace elements in streptozocin induced diabetic rats treated with Moringa oleifera leaf powder. WJPMR. 2020;6(12):15-8.links/5fcb587092851c00f8516430/EVALUATION-OF-SOME-TRACE-ELEMENTS-IN-STREPTOZOCIN-INDUCED-DIABETIC-RATS-TREATED-WITH-MORINGA-OLEIFERA-LEAF-POWDER.pdf.
22. Anyiam AF, Obeagu EI, Obi E, Omosigho PO, Irondi EA, Arinze-Anyiam OC, Asiyah MK. ABO blood groups and gestational diabetes among pregnant women attending University of Ilorin Teaching Hospital, Kwara State, Nigeria. International Journal of Research and Reports in Hematology. 2022;5(2):113-21.
23. Okafor CJ, Yusuf SA, Mahmoud SA, Salum SS, Vargas SC, Mathew AE, Obeagu EI, Shaib HK, Iddi HA, Moh'd MS, Abdulrahman WS. Effect of Gender and Risk Factors in Complications of Type 2 Diabetic Mellitus among Patients Attending Diabetic Clinic in Mnazi Mmoja Hospital,

Zanzibar. Journal of Pharmaceutical Research International. 2021;33(29B):67-78.
24. Galano ES, Yusuf SA, Ogbonnia SO, Ogundahunsi OA, Obeagu EI, Chukwuani U, Okafor CJ, Obianagha NF. Effect of Extracts of Kigelia Africana Fruit and Sorghum Bicolor Stalk on the Biochemical Parameters of Alloxan-Induced Diabetic Rats. Journal of Pharmaceutical Research International. 2021;33(25B):86-97.
25. Kama SC, Obeagu EI, Alo MN, Ochei KC, Ezugwu UM, Odo M, Ikpeme M, Ukeekwe CO, Amaeze AA. Incidence of Urinary Tract Infection among Diabetic Patients in Abakaliki Metropolis. Journal of Pharmaceutical Research International. 2020;32(28):117-21.
26. Nwakulite A, Obeagu EI, Eze R, Vincent CC, Chukwurah EF, Okafor CJ, Ibekwe AM, Adike CN, Chukwuani U, Ifionu BI. Evaluation of Catalase and Manganese in Type 2 Diabetic Patients in University of Port Harcourt Teaching Hospital. Journal of Pharmaceutical Research International. 2021:40-45.
27. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023 Jun 10;6(2):10-3.
28. Obeagu EI, Mohamod AH. An update on Iron deficiency anaemia among children with congenital heart disease. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(4):45-8.
29. Edward U, Osuorji VC, Nnodim J, Obeagu EI. Evaluationof Trace Elements in Sickle Cell Anaemia Patients Attending Imo State Specialist Hospital, Owerri. Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035. 2022 Mar 4;2(1):218-34.
30. Obeagu EI. Vaso-occlusion and adhesion molecules in sickle cells disease. Int J Curr Res Med Sci. 2018;4(11):33-5.
31. Ifeanyi OE, Stella EI, Favour AA. Antioxidants In The Management of Sickle Cell Anaemia. Int J Hematol Blood Disord (Internet) 2018 (cited 2021 Mar 4); 3. Available from: https://symbiosisonlinepublishing. com/hematology/hema tology25. php. 2018 Sep.
32. Nnodim J, Uche U, Ifeoma U, Chidozie N, Ifeanyi O, Oluchi AA. Hepcidin and erythropoietin level in sickle cell disease. British Journal of Medicine and Medical Research. 2015 Jan 10;8(3):261-5.
33. Obeagu EI. BURDEN OF CHRONIC OSTEOMYLITIS: REVIEW OF ASSOCIATIED FACTORS. Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035. 2023 Jan 1;3(1):1-6.
34. Aloh GS, Obeagu EI, Okoroiwu IL, Odo CE, Chibunna OM, Kanu SN, Elemchukwu Q, Okpara KE, Ugwu GU. Antioxidant-Mediated Heinz Bodies Levels of Sickle Erythrocytes under Drug-Induced Oxidative Stress. European Journal of Biomedical and Pharmaceutical sciences. 2015;2(1):502-7.
35. Umar MI, Aliyu F, Abdullahi MI, Aliyu MN, Isyaku I, Aisha BB, Sadiq RU, Shariff MI, Obeagu EI. ASSESSMENT OF FACTORS PRECIPITATING SICKLE CELL CRISES AMONG UNDER 5-YEARS CHILDREN ATTENDING SICKLE CELL CLINIC OF MURTALA MUHAMMAD SPECIALIST HOSPITAL, KANO. blood. 2023;11:16.
36. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sickle Cell Anaemia. Newport International Journal of Scientific and Experimental Sciences (NIJSES). 2023;3(2):56-9.
37. Obeagu EI, Obeagu GU. Evaluation of Hematological Parameters of Sickle Cell Anemia Patients with Osteomyelitis in A Tertiary Hospital in Enugu, Nigeria. Journal of Clinical and Laboratory Research. 2023;6(1):2768-0487.
38. Nwakulite A, Obeagu EI, Nwanjo HU, Nwosu DC, Nnatuanya IN, Vincent CC, Amaechi CO, Ochiabu O, Barbara MT, Ibekwe AM, Okafor CJ. Studies on Pancreatic Gene Expression in Diabetic Rats Treated with Moringa oleifera Leaf. Journal of Pharmaceutical Research International. 2021;33(28A):78-86.

39. Nwosu DC, Nwanjo HU, Obeagu EI, Ugwu GU, Ofor IB, Okeke A, Ochei KC, Kanu SN, Okpara KE. Evaluation of Lipoprotein A and Lipid Tetrad Index Pattern in Diabetic Patients Attending Metabolic Clinic in The Federal Medical Centre, Owerri, Imo State.World Journal of Pharmacy and Pharmaceutical Sciences, 2015; 4 (3):126-140
40. Ezema GO, Omeh NY, Egbachukwu S, Agbo EC, Ikeyi AP, Obeagu EI. Evaluation of Biochemical Parameters of Patients with Type 2 Diabetes Mellitus Based on Age and Gender in Umuahia. Asian Journal of Dental and Health Sciences. 2023 Jun 15;3(2):32-6.http://ajdhs.com/index.php/journal/article/view/43.
41. Adu ME, Chukwuani U, Ezeoru V, Okafor CJ, Amaechi CO, Vincent CC, Obeagu GU, Eze R, Nnatuanya IN, Nwosu DC, Nwanjo HU. Studies on molecular docking of moringa oleifera leaf phytochemical constituents on alpha glucosidase, alpha amylase and dipeptidyl peptidase. Journal of Pharmaceutical Research International. 2021 May 7;33(28A):239-45.
42. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Obeagu EI. Plasma Level of Macromolecules and Mathematical Calculation of Potential Energy in Type 2 Diabetic Individuals at NAUTH, Nnewi, Nigeria. Journal of Pharmaceutical Research International. 2021 Nov 2;33(47B):242-8.
43. Nwakulite A, Obeagu EI, Eze R, Ugochi VE, Vincent CC, Okafor CJ, Chukwurah EF, Unaeze BC, Amaechi CO, Okwuanaso CB, Chukwuani U. Estimation of Serum Glutathione Peroxidase in Streptozotocin Induced Diabetic Rat Treated with Bitter Leaf Extract. Journal of Pharmaceutical Research International. 2021;33(30B):200-206.
44. Okoroiwu IL, Obeagu EI, San Miguel HG, Bote SA, Obeagu GU. Characterisation of HLA-DR antigen in patients type 1 diabetes mellitus in patient attending a tertairy hospital in Enugu, south-east Nigeria. ACADEMIC JOURNAL. 2023.
45. Okoroiwu IL, Obeagu EI, Obeagu GU, Chikezie CC, Ezema GO. The prevalence of selected autoimmune diseases. Int. J. Adv. Multidiscip. Res. 2016;3(3):9-14.
46. Nwakuilite A, Nwanjo HU, Nwosu DC, Obeagu EI. EVALUATION OF ENZYME ANTIOXIDANTS IN STREPTOZOCIN INDUCED DIABETIC RATS TREATED WITH MORINGA OLEIFERA LEAF POWDER. European Journal of Biomedical. 2020;7(11):285-8.
47. Nwosu DC, Nwanjo HU, Opara AU, Ofor IB, Obeagu EI, Ugwu GU, Ojiegbe GC, Nnorom RM, Nwokike GI, Okpara KE, Ochei KC. EVALUATION OF C-REACTIVE PROTEIN, SELENIUM AND GLYCOSYLATED HAEMOGLOBIN LEVELS IN DIABETIC PATIENTS ATTENDING METABOLIC CLINIC IN THE FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. **World Journal of Pharmacy and Pharmaceutical Sciences, 2015; 4 (3):141-152.**https://www.academia.edu/download/38320132/NWOSU_EMMA_9.pdf.
48. Nwakuilite A, Nwanjo HU, Nwosu DC, Obeagu EI. EVALUATION OF KIDNEY INJURY MOLECULE-1, CYSTATIN C, AND SERUM ELECTROLYTES IN STREPTOZOCIN INDUCED DIABETIC RATS TREATED WITH MORINGA OLEIFERA LEAF POWDER. Education. 2002.
49. Obeagu EI, Bot YS, Opoku D, Obeagu GU, Hassan AO. Sickle Cell Anaemia: Current Burden in Africa. International Journal of Innovative and Applied Research. 2023;11(2):12-4.
50. Gamde MS, Obeagu EI. Iron Deficiency Anaemia: Enemical to Pregnancy. European Journal of Biomedical. 2023;10(9):272-5.
51. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023 Jun 10; 6 (2): 10-3.

52. Obeagu EI, Ogbuabor BN, Ikechukwu OA, Chude CN. Haematological parameters among sickle cell anemia patients' state and haemoglobin genotype AA individuals at Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. International Journal of Current Microbiology and Applied Sciences. 2014;3(3):1000-5.
53. Ifeanyi OE, Nwakaego OB, Angela IO, Nwakaego CC. Haematological parameters among sickle cell anaemia... Emmanuel Ifeanyi1, et al. pdf• Obeagu. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1000-5.
54. Ugwu OP, Alum EU, Okon MB, Aja PM, Obeagu EI, Onyeneke EC. Anti-nutritional and gas chromatography-mass spectrometry (GC-MS) analysis of ethanol root extract and fractions of Sphenocentrumjollyanum. RPS Pharmacy and Pharmacology Reports. 2023 Apr 1;2(2):rqad007.
55. Obeagu EI, Scott GY, Amekpor F, Ugwu OP, Alum EU. Covid-19 Infection and Diabetes: A Current Issue. International Journal of Innovative and Applied Research. 2023;11(1):25-30.
56. Ugwu OP, Alum EU, Obeagu EI, Okon MB, Aja PM, Samson AO, Amusa MO, Adepoju AO. Effect of Ethanol leaf extract of Chromolaena odorata on lipid profile of streptozotocin induced diabetic wistar albino rats. IAA Journal of Biological Sciences. 2023;10(1):109-17.
57. Ifeanyi OE. Gestational Diabetes: Haematological Perspective. South Asian Research Journal of Applied Medical Sciences, 1 (2):41-42. DOI: 10.36346/SARJAMS.2019.v01i02.003 https://sarpublication.com/media/articles/SARJAMS_12_41-42.pdf.
58. Ogbu IS, Odeh EJ, Ifeanyichukwu OE, Ogbu C, Ude UA, Obeagu EI. Prevalence of prediabetes among first degree relatives of type 2 diabetes individuals in Abakaliki, Ebonyi State Nigeria. Academic Journal of Health Sciences: Medicina Balear. 2023;38(2):85-8. https://dialnet.unirioja.es/servlet/articulo?codigo=8845439.
59. Ifeanyi OE. An update on Diabetes Mellitus. Int. J. Curr. Res. Med. Sci. 2018;4(6):71-81.DOI: 10.22192/ijcrms.2018.04.06.012 links/5b3b97a04585150d23f63e76/An-update-on-Diabetes-Mellitus.pdf.
60. Nunemaker CS. Considerations for defining cytokine dose, duration, and milieu that are appropriate for modeling chronic low-grade inflammation in type 2 diabetes. Journal of Diabetes Research. 2016.
61. Aboderin FI, Oduola T, Davison GM, Oguntibeju OO. A Review of the Relationship between the Immune Response, Inflammation, Oxidative Stress, and the Pathogenesis of Sickle Cell Anaemia. Biomedicines. 2023;11(9):2413.
62. Issom DZ, Henriksen A, Woldaregay AZ, Rochat J, Lovis C, Hartvigsen G. Factors influencing motivation and engagement in mobile health among patients with sickle cell disease in low-prevalence, high-income countries: qualitative exploration of patient requirements. JMIR Human Factors. 2020;7(1):e14599.
63. Kimball JP, Inan OT, Convertino VA, Cardin S, Sawka MN. Wearable sensors and machine learning for hypovolemia problems in occupational, military and sports medicine: Physiological basis, hardware and algorithms. Sensors. 2022;22(2):442.
64. Oyedeji CI, Hodulik KL, Telen MJ, Strouse JJ. Management of Older Adults with Sickle Cell Disease: Considerations for Current and Emerging Therapies. Drugs & Aging. 2023;40(4):317-334.
65. Weaver SB, Nonyel NP, Rungkitwattanakul D. Roles of Pharmacists in the Management of Sickle Cell Disease in Adults: A Narrative Review. Journal of Pharmacy Technology. 2024:87551225231222437.

66. Zhou J, Han J, Nutescu EA, Galanter WL, Walton SM, Gordeuk VR, Saraf SL, Calip GS. Similar burden of type 2 diabetes among adult patients with sickle cell disease relative to African Americans in the US population: a six-year population-based cohort analysis. British journal of haematology. 20191;185(1):116-27.

Access this Article in Online	
	Website: www.ijcrcps.com
Quick Response Code	Subject: Haematology
DOI: 10.22192/ijcrcps.2024.11.02.003	

How to cite this article:
Emmanuel Ifeanyi Obeagu and Getrude Uzoma Obeagu. (2024). Improving Outcomes: Integrated Strategies for Diabetes and Sickle Cell Anemia. Int. J. Curr. Res. Chem. Pharm. Sci. 11(2): 20-29.
DOI: http://dx.doi.org/10.22192/ijcrcps.2024.11.02.003

